// App-Quantinova.ai

3080 : Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation.

Researchers

Presenter

  • Voravit Ratanatharathorn

Principal Investigators

  • Scott R. Solomon

  • Louie H. Yu

  • Shiva Patil

  • Commercialization

  • Yiping Sun

  • Elizabeth Armstrong

  • Angela Smith

  • Cesar O. Freytes

  • Agnes Elekes

  • Kazunobu Kato

  • Donna Reece

  • Juan J. Toro

  • Gorgun Akpek

  • Entezam A. Sahovic

  • Guido J. Tricot

  • Paul J. Shaughnessy

  • Darrell J. White

  • Tulio E. Rodriguez

Medical Centers

  • Texas Transplant Institute, San Antonio, TX

  • Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada

  • Division of Hematology, Queen Elizabeth II Health Sciences Ctr., Halifax, NS, Canada

Locations

  • United States

  • Canada

Companies

  • Otsuka Pharmaceutica

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Hepatic veno-occlusive disease with immunodeficiency

  • Multiple Myeloma

  • Parkinson's disease

  • Neutropenia

  • Peripheral neuropathy

  • Epilepsy

Biomarkers

  • Ubiquitin A-52 Residue Ribosomal Protein Fusion Product 1

Drug/Treatment

  • Lenalidomide

  • Thalidomide

  • Bortezomib

  • Melphalan

  • Busulfan

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved